Medtronic launches VERTEX SELECT CHROMALOY Plus Rods in the U.S.

Continuing its leadership in cervical spine medical device therapies, Medtronic, Inc. today announced the U.S

Read more...

BioMarin announces BMN-111 program for treatment of achondroplasia

BioMarin Pharmaceutical Inc.

Read more...

VertiFlex enrolls patients in Superion IDE clinical trial

VertiFlex, Inc., a leading innovator of minimally invasive and motion preserving spinal surgery technologies, today announced that 200 patients have been enrolled in its pivotal IDE clinical trial of the Superion Interspinous Spacer (ISS).

Read more...

Wenzel Spine receives FDA marketing clearance for VariLift Expandable Interbody Fusion System

Wenzel Spine, Inc., a medical device company focused on offering less invasive, stand-alone alternatives to traditional spinal fusion, today announced they have received 510K clearance to market the VariLift Expandable Interbody Fusion System.

Read more...

VertiFlex enrolls 150 patients in Superion Interspinous Spacer IDE clinical trial

VertiFlex, Inc., a leading innovator of minimally invasive and motion preserving spinal surgery technologies, today announced that 150 patients have been enrolled in its pivotal IDE clinical trial of the Superion Interspinous Spacer (ISS).

Read more...

Baxano closes $30M Series C round of venture funding

Baxano, Inc. today announced the closing of a $30 million Series C round of venture funding, led by new investor CMEA Capital.

Read more...

Baxano closes $30M Series C round of venture funding

Baxano, Inc. today announced the closing of a $30 million Series C round of venture funding, led by new investor CMEA Capital. Funds were also contributed by new investors Kaiser Permanente Ventures and Affinity Capital Management and existing investors Prospect Venture Partners, Three Arch Partners, and Kearny Venture Partners.

Read more...

CTT’s Calmare Pain Therapy Treatment shows promise against CIPN

Competitive Technologies, Inc.

Read more...

Competitive Technologies to raise over $5M to accelerate sales of Calmare Pain Therapy Treatment

Competitive Technologies, Inc. today announced that it has signed an agreement to raise over $5 million by selling 2 million shares of equity to Crisnic Fund, S.A.

Read more...

CTT’s Calmare Pain Therapy Treatment decreases pain associated with CIPN

Competitive Technologies, Inc. today announced the issuance of an abstract from a study which has shown the successful treatment of patients suffering from pain associated with chemotherapy-induced peripheral neuropathy using CTT’s Calmare Pain Therapy Treatment.

Read more...

Next Page »